Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes

Exclusion Criteria

• •Male Patients,
• •Unknown hormonal Receptors
• •Positive HER-2 (Score 3 in IHC or positive FISH)
• •Pregnant or breastfeeding patient, or in age of pregnancy or predicting to be pregnant in the 6 months after the end of treatment,
• •Patient not using contraceptive treatment during the treatment or after the 6 months after the end of treatment,
• •Patient is a ward,
• •Patient suffering from a non compatible disease with the enrollment in the study,
• •Cardiac, renal, medullar, respiratory or hepatic insufficiency, clinically significant cardiovascular disease (including myocardiac infarct, unstable angina, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia) \< 1 year before the study enrollment or randomisation,
• •Patient with pulmonary lymphangitis or symptomatic pleural effusion (grade≥2), meningeal known carcinoma or symptoms of cerebromeningeal invasion, brain metastases unless treatment and stability for at least 4 weeks (no steroids or anti-convulsive).
• •Uncontrolled diabetes,
• •Psychiatric or neurological significant abnormality,
• •Peripheric Neuropathy \> grade 2,
• •Antecedent of hypersensibility to one of study treatment or one of used excipients,
• •Urinary tract infection or acute hemorrhagic cystitis in progress
• •Concomitant treatment with a medicine containing phenytoin or medication received in the context of a trial, or participation in another therapeutic clinical trial within \<30 days prior treatment with chemotherapy.
• •Geographically unstable patient in the next 6 months or remaining distance to the treatment center making it difficult to follow in the study,
• •Known history of abuse of narcotic or other drug or alcohol
• •History of surgery within 28 days before the start of treatment,
• •Patient unwilling or unable to comply with the requirements of the study.